Structure Therapeutics Inc. (GPCR) Cash Flow Statement
Structure Therapeutics Inc. (GPCR) generated -$220.3M of operating cash flow over the twelve months to 2026-06-30, spent $4.2M on capital expenditure and had free cash flow of -$224.5M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
GPCRStructure Therapeutics Inc.Follow GPCR — free
—
Price chart with a free account
- Market cap
- 1.5B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -0.08 | -0.12 | -0.22 | -0.22 | |
| Capital expenditure | 0.00 | 0.00 | 0.00 | -0.00 | |
| Free cash flow | -0.08 | -0.12 | -0.23 | -0.22 | |
| Stock-based compensation | 0.01 | 0.02 | 0.03 | — |
USD billions · SEC XBRL
Structure Therapeutics Inc. — questions
- What is Structure Therapeutics Inc.'s operating cash flow?
- -$220.3M over the twelve months to 2026-06-30.
- How much does Structure Therapeutics Inc. spend on capital expenditure?
- $4.2M over the twelve months to 2026-06-30.
- What is Structure Therapeutics Inc.'s free cash flow?
- -$224.5M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Structure Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.